BFEC
STAB

Benjamin F. Edwards & Company’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Benjamin F. Edwards & Company’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-500
Closed -$1K – 1601
2017
Q2 		$1K Buy
+500
New +$1.63K ﹤0.01% 1436

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $150M AUM 32.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WA
Winfield Associates Cleveland, Ohio $276M AUM 15.18% 1-Year Est. Return

Benjamin F. Edwards & Company's STAB Position: Q3 2017 in Review

Benjamin F. Edwards & Company sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q3 2017, closing a stake of 500 shares — an estimated $1K sold.

Benjamin F. Edwards & Company first reported a position in STAB in Q2 2017 and held it in 1 quarter. The position peaked at $1K in Q2 2017. 19 funds tracked by Wall St. Rank hold STAB as of Q3 2017.

  • Benjamin F. Edwards & Company reported no remaining Statera Biopharma, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 500 Statera Biopharma, Inc. Common Stock shares in Q3 2017, an estimated $1K.
  • Benjamin F. Edwards & Company first reported a position in Statera Biopharma, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Benjamin F. Edwards & Company's Statera Biopharma, Inc. Common Stock position peaked at $1K in Q2 2017.
  • 19 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q3 2017.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2017, filed 24 Oct 2017.